Suppr超能文献

现代时代霍奇金淋巴瘤的诊断。

Diagnosis of Hodgkin lymphoma in the modern era.

机构信息

From the Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

出版信息

Br J Haematol. 2019 Jan;184(1):45-59. doi: 10.1111/bjh.15614. Epub 2018 Nov 8.

Abstract

The Hodgkin lymphomas are a family of unique lymphoma subtypes, in which the nature of the neoplastic cell was enigmatic for many years. Much of the mystery has been solved, with all forms now considered to be of B-cell origin, in most cases of germinal centre derivation. Today we recognize Hodgkin lymphoma as an eponym that encompasses multiple entities. One of the unifying themes is the major contribution from the tumour microenvironment. Both the character of the neoplastic cells and the nature of the immune environment are critical to accurate diagnosis. Moreover, an understanding of the molecular alterations that characterize both the neoplastic cells and their microenvironment have led to therapeutic advances, targeting both neoplastic and reactive components. Other conditions may foster a similar inflammatory milieu and lead to lymphoproliferations that mimic the Hodgkin lymphomas. In this review we provide an update on the diagnostic features of the various subtypes and include additional information relevant for prognostic evaluation and investigation of potential therapeutic targets. Additionally, we also discuss those conditions that often cause confusion in diagnosis and need to be distinguished from the Hodgkin lymphomas.

摘要

霍奇金淋巴瘤是一组独特的淋巴瘤亚型,其中肿瘤细胞的性质多年来一直是个谜。随着所有形式的霍奇金淋巴瘤现在都被认为起源于 B 细胞,大多数情况下起源于生发中心,大部分谜团已经被解开。如今,我们认识到霍奇金淋巴瘤是一个包含多种实体的名称。其中一个统一的主题是肿瘤微环境的主要贡献。肿瘤细胞的特征和免疫环境的性质对准确诊断都至关重要。此外,对特征性肿瘤细胞及其微环境的分子改变的认识,导致了针对肿瘤细胞和反应性成分的治疗进展。其他情况可能会促进类似的炎症环境,并导致类似于霍奇金淋巴瘤的淋巴增殖。在这篇综述中,我们提供了各种亚型的诊断特征的最新信息,并包括了与预后评估和潜在治疗靶点研究相关的其他信息。此外,我们还讨论了那些在诊断中经常引起混淆并需要与霍奇金淋巴瘤区分开来的情况。

相似文献

1
Diagnosis of Hodgkin lymphoma in the modern era.
Br J Haematol. 2019 Jan;184(1):45-59. doi: 10.1111/bjh.15614. Epub 2018 Nov 8.
6
American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma.
Ann Diagn Pathol. 2019 Apr;39:105-110. doi: 10.1016/j.anndiagpath.2019.02.001. Epub 2019 Feb 6.
7
Pitfalls in diagnostic hematopathology -- Part II.
Int J Clin Exp Pathol. 2009 Sep 10;3(1):39-46.
8
Diagnostic utility of STAT6 expression in classical Hodgkin lymphoma and related entities.
Mod Pathol. 2020 May;33(5):834-845. doi: 10.1038/s41379-019-0428-0. Epub 2019 Dec 10.
10
Nodular lymphocyte predominant Hodgkin lymphoma: diagnostic pearls and pitfalls.
Arch Pathol Lab Med. 2010 Oct;134(10):1434-9. doi: 10.5858/2010-0207-OA.1.

引用本文的文献

1
Assessment of CD20 Marker as a Prognostic Predictor for Patients with Classical Hodgkin Lymphoma.
Cancer Manag Res. 2025 Aug 22;17:1767-1776. doi: 10.2147/CMAR.S531465. eCollection 2025.
3
4
Overview of Molecular Diagnostics in Irish Clinical Oncology.
HRB Open Res. 2025 Jun 9;7:16. doi: 10.12688/hrbopenres.13822.2. eCollection 2024.
5
A Rare Case of Hodgkin Lymphoma With Isolated Epitrochlear Lymphadenopathy. Our Experience and Main Differential Diagnosis.
Case Rep Med. 2025 Jul 10;2025:5548125. doi: 10.1155/carm/5548125. eCollection 2025.
6
Tumor-Associated Macrophages as Key Modulators of Disease Progression in Diffuse Large B-Cell Lymphoma.
Biomedicines. 2025 May 1;13(5):1099. doi: 10.3390/biomedicines13051099.
10
Flow Cytometry for B-Cell Non-Hodgkin and Hodgkin Lymphomas.
Cancers (Basel). 2025 Feb 26;17(5):814. doi: 10.3390/cancers17050814.

本文引用的文献

1
Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?
Blood. 2018 Nov 1;132(18):1871-1878. doi: 10.1182/blood-2018-04-842559. Epub 2018 Aug 6.
2
Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma.
Front Oncol. 2018 Jun 4;8:193. doi: 10.3389/fonc.2018.00193. eCollection 2018.
3
Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells.
J Clin Invest. 2018 Jul 2;128(7):2996-3007. doi: 10.1172/JCI95993. Epub 2018 Jun 11.
4
Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.
Blood. 2018 May 31;131(22):2454-2465. doi: 10.1182/blood-2017-11-814913. Epub 2018 Apr 12.
5
Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies.
Blood. 2018 Apr 12;131(15):1654-1665. doi: 10.1182/blood-2017-09-772632. Epub 2018 Mar 2.
6
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.
Blood. 2018 May 31;131(22):2413-2425. doi: 10.1182/blood-2017-11-812073. Epub 2018 Feb 15.
7
A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.
Haematologica. 2018 May;103(5):840-848. doi: 10.3324/haematol.2017.180554. Epub 2018 Jan 19.
8
Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.
Blood Adv. 2017 Dec 11;1(26):2600-2609. doi: 10.1182/bloodadvances.2017009472. eCollection 2017 Dec 12.
9
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
Blood. 2017 Nov 30;130(22):2420-2430. doi: 10.1182/blood-2017-03-770719. Epub 2017 Sep 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验